Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30,579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumors.
Karagiannis D, Wu W, Li A, Hayashi M, Chen X, Yip M, Mangipudy V, Xu X, Sánchez-Rivera FJ, Soto-Feliciano YM, Ye J, Papagiannakopoulos T, Lu C. Karagiannis D, et al. Among authors: wu w. bioRxiv [Preprint]. 2023 Apr 28:2023.04.24.538118. doi: 10.1101/2023.04.24.538118. bioRxiv. 2023. Update in: Cell Rep. 2024 Jan 23;43(1):113629. doi: 10.1016/j.celrep.2023.113629 PMID: 37162970 Free PMC article. Updated. Preprint.
Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer.
Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG, Papagiannakopoulos T. Sayin VI, et al. Among authors: wu wl. Elife. 2017 Oct 2;6:e28083. doi: 10.7554/eLife.28083. Elife. 2017. PMID: 28967864 Free PMC article.
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, Hayashi M, Rajalingam S, Karakousi T, Sayin VI, Khanna KM, Wong KK, Wild R, Tsirigos A, Poirier JT, Rudin CM, Davidson SM, Koralov SB, Papagiannakopoulos T. Pillai R, et al. bioRxiv [Preprint]. 2023 Jun 28:2023.06.27.546750. doi: 10.1101/2023.06.27.546750. bioRxiv. 2023. Update in: Sci Adv. 2024 Mar 29;10(13):eadm9859. doi: 10.1126/sciadv.adm9859 PMID: 37425844 Free PMC article. Updated. Preprint.
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth.
Rashidfarrokhi A, Pillai R, Hao Y, Wu WL, Karadal-Ferrena B, Dimitriadoy SG, Cross M, Yeaton AH, Huang SM, Bhutkar AJ, Herrera A, Rajalingam S, Hayashi M, Huang KL, Bartnicki E, Zavitsanou AM, Wohlhieter CA, Leboeuf SE, Chen T, Loomis C, Mezzano V, Kulicke R, Davis FP, Stransky N, Smolen GA, Rudin CM, Moreira AL, Khanna KM, Pass HI, Wong KK, Koide S, Tsirigos A, Koralov SB, Papagiannakopoulos T. Rashidfarrokhi A, et al. bioRxiv [Preprint]. 2023 Jul 17:2023.07.15.549147. doi: 10.1101/2023.07.15.549147. bioRxiv. 2023. PMID: 37502974 Free PMC article. Preprint.
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, Hayashi M, Rajalingam S, Karakousi T, Sayin VI, Khanna KM, Wong KK, Wild R, Tsirigos A, Poirier JT, Rudin CM, Davidson SM, Koralov SB, Papagiannakopoulos T. Pillai R, et al. Sci Adv. 2024 Mar 29;10(13):eadm9859. doi: 10.1126/sciadv.adm9859. Epub 2024 Mar 27. Sci Adv. 2024. PMID: 38536921 Free PMC article.
30,579 results
You have reached the last available page of results. Please see the User Guide for more information.